Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM)

Running, not enrolling

Conditions studied: Metastatic Solid Tumor, SF3B1 Gene Mutation, Spliceosome Mutation, U2AF1 Gene Mutation, SRSF2 Gene Mutation

In brief

This study is being done to see if patients with metastatic solid tumors (hematologic malignancies and lymphoma excluded) who have a specific genetic mutation in patients' tumor (the SF3B1, U2AF1 or SRSF2 mutation), are more likely to respond to immunotherapy agents that are now commercially available.

Key facts

Study ID

NCT04447651

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

6

Starts

2020-09-17

Expected to finish

2027-08-01

Last updated by the study team

2026-07-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Performance status eligible for immune checkpoint blockade as determined by local physician
• Able to demonstrate histologically proven locally advanced or metastatic solid tumors (hematologic malignancies and lymphoma excluded)
• genomic testing demonstrating a spliceosome mutation (SF3B1, U2AF1 or SRSF2)

You may not qualify if…

• Local physician determines has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
• Local physician determines the patient has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate

Where it is running

• Johns Hopkins University — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.